Regeneron Pharmaceuticals, Inc. (REGN) Stock Price, News, Analysis

Technical Score (1D)

BUY

News Sentiment

MIXED

Piper Sandler trimmed its price target for Regeneron by $1 to $854, signaling a slight reassessment of the company’s valuation, and investors should keep an eye on the upcoming earnings release for guidance and pipeline updates. The downgrade in the mean target to $826.5 reported by one source introduces uncertainty about the overall valuation consensus, which could lead to short‑term volatility as traders reconcile the differing estimates. Because the rating stance remains overweight, the move is unlikely to trigger a large shift in investor sentiment, but it does suggest that analysts are slightly tightening growth expectations. The modest price target adjustment reflects updated expectations for near‑term earnings, which could influence short‑term trading as the market digests the new valuation. Regeneron’s pipeline remains a key driver of its valuation, so any new data on its COVID‑19 antibody or oncology programs could quickly reverse the current neutral sentiment. Analysts are also monitoring the company’s cash burn and capital allocation plans, as changes there could affect the perceived risk profile and alter the price target further. The slight downward tweak in the target may prompt institutional investors to rebalance their portfolios, potentially creating a short‑term buying opportunity if the stock trades below the new target. In the next 1–10 trading days, traders should watch for the earnings call, any pipeline updates, and any commentary from other analysts that may confirm or refute the current valuation consensus. Additionally, keep an eye on any regulatory developments that could impact the approval timeline for Regeneron’s key products, as such news would likely have a material effect on the stock’s valuation.

REGN|Company Info

Sector

Healthcare

Industry

Biotechnology

Exchange

NMS

Country

United States

Website

regeneron.com

Symbol

REGN

Description

Regeneron Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for a range of serious diseases. The company's core value proposition lies in its diverse portfolio of marketed products, including EYLEA for eye diseases and Dupixent for conditions like atopic dermatitis and asthma. Regeneron also offers treatments for various cancers, rheumatoid arthritis, and other rare diseases, demonstrating its commitment to addressing unmet medical needs. Through strategic collaborations, the company is actively pursuing advancements in gene editing and cell therapies, further solidifying its position in the competitive pharmaceutical landscape. Headquartered in Tarrytown, New York, Regeneron aims to improve patient outcomes through its comprehensive research and development efforts.

REGN|Earnings Snapshot

Earnings Summary

Regeneron Pharmaceuticals, a biopharmaceutical firm headquartered in Tarrytown, New York, develops and markets innovative medicines for serious diseases such as eye disorders, atopic dermatitis, asthma, and various cancers, positioning itself as a key player in the biotechnology sector. In the most recent earnings cycle, Regeneron reported Q4 2025 revenue of $3.884 billion, slightly above the $3.866 billion estimate, and EPS of $11.44 versus the $10.84 forecast, marking a modest revenue uptick and a strong earnings beat; Q1 2026 revenue rose to $3.606 billion from $3.029 billion in Q1 2025, a 19.5% increase, while EPS of $9.47 fell short of the $8.90 estimate, indicating a slight earnings miss amid robust top‑line growth. Compared to the prior two quarters (Q2 2025 and Q3 2025), revenue has accelerated from $3.676 billion to $3.754 billion, yet EPS swung from a $12.89 beat in Q2 2025 to a $11.83 beat in Q3 2025, and then to a miss in Q1 2026, reflecting a pattern of revenue expansion coupled with fluctuating earnings performance. Historically, Regeneron has maintained double‑digit YoY revenue growth over the past four quarters, consistently beating analyst EPS estimates in three of the last four reports, though the most recent quarter shows a deviation from that trend; the company’s pipeline, particularly Dupixent and emerging oncology candidates, continues to underpin investor confidence. Recent analyst commentary—Piper Sandler, HSBC, Morgan Stanley, and Truist Securities—all trimmed price targets to the $730–$854 range while retaining overweight or buy ratings, signaling a cautious near‑term valuation outlook that may dampen short‑term enthusiasm; the consensus remains that pipeline developments and potential M&A activity could offset this tightening. Investors should watch the upcoming Q2 2026 earnings release for guidance on sales projections, any updates on key drug candidates, and commentary on capital allocation, as these factors will be critical in determining whether Regeneron can sustain its revenue growth while restoring EPS momentum.}}

Read full report

EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$10.61	-	-
Q1'26	$8.90	$9.47	+6.4%
Q4'25	$10.84	$11.44	+5.5%
Q3'25	$9.64	$11.83	+22.7%
Q2'25	$8.44	$12.89	+52.7%
Q1'25	$8.48	$8.22	-3.0%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$3.9B	-	-
Q1'26	$3.5B	$3.6B	+3.5%
Q4'25	$3.9B	$3.9B	+0.4%
Q3'25	-	$3.8B	-
Q2'25	-	$3.7B	-
Q1'25	-	$3.0B	-

Full Earnings BreakdownEstimates, actuals, guidance, and historical context

→

Market Data

REGN Stock Snapshot

REGN is currently trading at $664.52, giving Regeneron Pharmaceuticals, Inc. a market cap of 69.67B and a P/E ratio of 15.8. Today's range spans $658.50–$676.66, with shares opening at $672.67 and moving down $0.02 (0.0%) from the prior close. DailyIQ's technical score sits at 59/100 (HOLD) with a news sentiment reading of 49/100.

Over the past year REGN has traded between $541.00 and $821.11 - the current price is +22.8% off the 52-week low and -19.1% from the high. 40 analysts cover the stock with a Buy consensus and a mean 12-month target of $822.48 (range $641.00–$1000.00), implying upside of +23.8%.

Regeneron Pharmaceuticals, Inc. (REGN) has 69.67B in Healthcare market capitalization and is currently neutral on the technical dashboard: 59/100, HOLD, price $664.52 (in the middle of its 52-week range). Sentiment reads neutral at 49/100. (P/E: 15.8) In this tier, quiet accumulation often happens in HOLD phases - active managers who want to build positions without signaling do it here, where the price isn't trending and volume patterns are easier to hide. Annual range: $541.00–$821.11.

Portfolio construction in Healthcare often uses large-cap names like REGN as tactical swing positions during neutral phases: cheap enough to overweight, liquid enough to exit quickly, and large enough to provide meaningful sector beta. The current 59/100 (HOLD) at $664.52 (in the middle of its 52-week range) and neutral sentiment (49/100) frame the position as a catalyst play within the $541.00–$821.11 annual range rather than a directional bet.

News Sentiment Analysis

Sentiment gathered from recent headlines

49/100

Strong NegativeNeutralStrong Positive

MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

Piper Sandler maintains an Overweight rating on Regeneron (REGN) but trims its price target from $855 to $854, indicating a modest reassessment of the company’s valuation. The slight reduction reflects updated expectations for growth and earnings, though the rating stance remains unchanged. Traders should watch for the upcoming earnings release to gauge revenue guidance and any pipeline updates that could influence the target further.

What did this article say?

Piper Sandler reduced its price target for Regeneron from $855 to $854, reflecting a modest downgrade. The brokerage maintains an overweight rating but lowered the mean target to $826.5. This adjustment signals a slight shift in expectations for Regeneron's near‑term performance, potentially impacting investor sentiment.

What did this article say?

No summary available yet for this article.

What did this article say?

Morgan Stanley retains an Equal-Weight rating on Regeneron (REGN) but reduces its price target from $788 to $730, signaling a more pronounced valuation adjustment. The cut reflects concerns over competitive dynamics and potentially slower sales growth. Traders should monitor the forthcoming earnings report for updated guidance and any regulatory developments that could impact the company’s outlook.

What did this article say?

Morgan Stanley reduced its price target for Regeneron Pharmaceuticals (REGN) from $788 to $730 while keeping an equal‑weight rating. The downgrade reflects a reassessment of the company’s near‑term valuation, despite its strong pipeline and recent clinical successes. The move signals a more cautious outlook for the next 12 months, though the firm still views REGN as a solid long‑term play.

What did this article say?

Jim Cramer predicts a wave of biotech mergers and acquisitions as the FDA environment becomes more favorable. He cites Regeneron’s confirmed‑data franchises, such as Dupixent, as assets that could command premium acquisition prices. The analyst notes that other major players like Lilly and Gilead are already active in large deals, suggesting a competitive landscape. This outlook implies potential upside for Regeneron if it participates in or benefits from upcoming M&A activity.

What did this article say?

Regeneron (REGN) continues its track record of earnings surprises, with analysts noting a strong pipeline and robust revenue growth. The company’s recent drug approvals and expanding indications support expectations of a positive earnings beat. Investors should monitor the upcoming earnings release for guidance on sales projections and any updates on regulatory approvals. Additionally, watch for any commentary on the company’s strategic initiatives, such as potential collaborations or new product launches.

What did this article say?

Truist Securities lowered Regeneron Pharmaceuticals’ price target to $769 from $778, indicating a modest downgrade. The adjustment reflects a slight shift in the firm’s outlook, possibly tied to recent earnings or pipeline developments. Investors should watch for Regeneron’s upcoming earnings release for updated financial guidance. Additionally, any new data on key drug candidates could influence the stock’s trajectory.

What did this article say?

RBC Capital reduced Regeneron’s price target to $696 while keeping a sector‑perform rating, signaling modest concerns about near‑term growth.

What did this article say?

RBC Capital has reduced its price target for Regeneron Pharmaceuticals (REGN) from $707 to $696 while keeping a sector perform rating. The downgrade reflects a modest downward view on the company’s near‑term prospects, though the overall rating remains overweight. The firm’s mean target for REGN sits at $829.2, suggesting a broader market optimism despite the recent cut. Traders should note the slight adjustment as a potential signal of valuation tightening and watch for any subsequent earnings guidance that could confirm or reverse this stance.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

No summary available yet for this article.

What did this article say?

RBC Capital reduced Regeneron’s price target to $696 while keeping a sector‑perform rating, signaling modest concerns about near‑term growth.

What did this article say?

REGN·Regeneron Pharmaceuticals, Inc.

EPS

Revenue

REGN Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Discover More

News Sentiment Analysis

Recent News Coverage

Discover More